Navidea Biopharmaceuticals, Inc. (NAVB): Price and Financial Metrics
GET POWR RATINGS... FREE!
NAVB Stock Summary
- NAVB has a higher market value than only 2.67% of US stocks; more precisely, its current market capitalization is $9,385,665.
- With a price/sales ratio of 81.34, NAVIDEA BIOPHARMACEUTICALS INC has a higher such ratio than 97.19% of stocks in our set.
- As for revenue growth, note that NAVB's revenue has grown -83.53% over the past 12 months; that beats the revenue growth of merely 1.67% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to NAVIDEA BIOPHARMACEUTICALS INC, a group of peers worth examining would be HSTO, BJDX, NURO, AIM, and GEOS.
- NAVB's SEC filings can be seen here. And to visit NAVIDEA BIOPHARMACEUTICALS INC's official web site, go to www.navidea.com.
NAVB Valuation Summary
- NAVB's price/sales ratio is 80.9; this is 1486.27% higher than that of the median Healthcare stock.
- Over the past 243 months, NAVB's price/sales ratio has gone up 80.
Below are key valuation metrics over time for NAVB.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| NAVB | 2023-01-30 | 80.9 | -2.0 | -0.5 | -0.4 |
| NAVB | 2023-01-27 | 76.5 | -1.9 | -0.5 | -0.4 |
| NAVB | 2023-01-26 | 79.1 | -1.9 | -0.5 | -0.4 |
| NAVB | 2023-01-25 | 74.8 | -1.8 | -0.5 | -0.4 |
| NAVB | 2023-01-24 | 76.5 | -1.9 | -0.5 | -0.4 |
| NAVB | 2023-01-23 | 73.9 | -1.8 | -0.5 | -0.4 |
NAVB Growth Metrics
- Its year over year net cashflow from operations growth rate is now at 5.57%.
- Its 4 year price growth rate is now at -88.89%.
- Its 2 year revenue growth rate is now at -47.21%.
The table below shows NAVB's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 0.11539 | -9.281866 | -17.38457 |
| 2022-06-30 | 0.204256 | -9.436224 | -12.0767 |
| 2022-03-31 | 0.407776 | -9.711727 | -11.75128 |
| 2021-12-31 | 0.531513 | -10.21815 | -11.73093 |
| 2021-09-30 | 0.700416 | -10.04659 | -11.08244 |
| 2021-06-30 | 0.872423 | -10.66532 | -11.9495 |
NAVB Stock Price Chart Interactive Chart >
NAVB Price/Volume Stats
| Current price | $0.29 | 52-week high | $1.24 |
| Prev. close | $0.29 | 52-week low | $0.16 |
| Day low | $0.28 | Volume | 113,800 |
| Day high | $0.31 | Avg. volume | 225,860 |
| 50-day MA | $0.26 | Dividend yield | N/A |
| 200-day MA | $0.48 | Market Cap | 9.32M |
Navidea Biopharmaceuticals, Inc. (NAVB) Company Bio
Navidea Biopharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision radiopharmaceutical diagnostics for diseases such as cancer.
Latest NAVB News From Around the Web
Below are the latest news stories about NAVIDEA BIOPHARMACEUTICALS INC that investors may wish to consider to help them evaluate NAVB as an investment opportunity.
The Navidea Biopharmaceuticals Inc. (NAVB) had a good session last reading, didn’t it?Navidea Biopharmaceuticals Inc. (AMEX:NAVB) marked $0.27 per share on Tuesday, up from a previous closing price of $0.21. While Navidea Biopharmaceuticals Inc. has overperformed by 28.57%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NAVB fell by -73.00%, with highs and lows ranging from $1.27 to […] |
Navidea stock soars ~25% on upcoming US patent linked to cancer drug pipelineNavidea Biopharmaceuticals (NAVB) stock rose ~25% after the company said it received a notice of allowance from the U.S |
Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Key Component of the Company’s Cancer Immunotherapy PipelineDUBLIN, Ohio, January 03, 2023--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application titled, "Compositions And Methods For Altering Macrophage Phenotype (US Application #16/832,620)." Broadly, this patent covers the ability of Navidea’s const |
Navidea Biopharmaceuticals, Inc. (AMEX:NAVB) Q3 2022 Earnings Call TranscriptNavidea Biopharmaceuticals, Inc. (AMEX:NAVB) Q3 2022 Earnings Call Transcript November 15, 2022 Operator: Greetings and welcome to the Navidea Biopharmaceuticals’ Quarter Three Earnings Call and Business Update. And as a reminder this conference call is being recorded. It is now my pleasure to introduce Dr. Michael Rosol, Chief Medical Officer. Thank you, Michael. You may […] |
Navidea Biopharmaceuticals Files Appeal in CRG CaseDUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on November 29, 2022, Navidea and its majority-owned subsidiary Macrophage Therapeutics, Inc. filed an appeal of the judgment by the District Court of Harris County, Texas in Case No. 2018-24442-151; Capital Royalty Partners II, L.P. et al. v. Navidea Biopharmaceu |
NAVB Price Returns
| 1-mo | N/A |
| 3-mo | 22.16% |
| 6-mo | -49.17% |
| 1-year | -69.98% |
| 3-year | -75.83% |
| 5-year | -95.97% |
| YTD | 38.10% |
| 2022 | -79.00% |
| 2021 | -53.49% |
| 2020 | 70.63% |
| 2019 | -37.00% |
| 2018 | -72.22% |
Continue Researching NAVB
Here are a few links from around the web to help you further your research on Navidea Biopharmaceuticals Inc's stock as an investment opportunity:Navidea Biopharmaceuticals Inc (NAVB) Stock Price | Nasdaq
Navidea Biopharmaceuticals Inc (NAVB) Stock Quote, History and News - Yahoo Finance
Navidea Biopharmaceuticals Inc (NAVB) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...